Recruiting

EUS & Ablation

Sponsor:

West Virginia University

Code:

NCT07625189

Conditions

RFA

Microwave Ablation

Pancreatic Lesion

Gastrointestinal Lesions

Ablation Techniques

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This is a single-center, investigator-initiated, prospective observational registry that will collect longitudinal clinical data on adult patients (≥18 years) undergoing endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic and other gastrointestinal/hepatobiliary lesions as part of routine clinical care. The registry will not alter standard-of-care management. Data will be abstracted from the medical record and routine clinical systems. Primary outcomes include change in target lesion size on clinically obtained imaging and overall survival following ablation. Secondary outcomes include changes in tumor biomarkers, adverse events, non-target lesion changes, and patient-reported symptoms.

Conditions

RFA

Microwave Ablation

Pancreatic Lesion

Gastrointestinal Lesions

Ablation Techniques

Study ID

NCT07625189

Start date

Mar 10, 2026

Status verified date

May, 2026

Completion date

Mar, 2028

Anticipated

Primary completion date

Mar, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults ≥ 18 years of age.
  • Diagnosis of a pancreatic premalignant lesion or malignancy, and other gastrointestinal or hepatobiliary lesion for which EUS-guided ablation is planned as part of standard clinical care.
  • At least one clinically identified target lesion for which RFA or MWA is performed.

Exclusion Criteria:

  • In the judgment of the treating clinician, inclusion in the registry would not be appropriate
  • The individual is expected to be unable to complete routine clinical follow-up.

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Change From Baseline to 1 Month in Target Lesion Size [ Time Frame: Baseline to 1 month ]
  • Change From Baseline to 3 Months in Target Lesion Size [ Time Frame: Baseline to 3 months ]
  • Change From Baseline to 6 Months in Target Lesion Size [ Time Frame: Baseline to 6 months ]
  • Change From Baseline to 12 Months in Target Lesion Size [ Time Frame: Baseline to 12 months ]
  • Overall Survival [ Time Frame: From ablation to death or last follow-up, assessed up to 1 year ]
  • Overall Survival [ Time Frame: From ablation to death or last follow-up, assessed up to 3 year ]

Central Contacts and Locations

Central contacts

Zim Warda Hasan

364-203-1900zh00027@mix.wvu.edu

Locations

West Virginia University

Recruiting

Morgantown, West Virginia, United States, 26505

More Information

Sponsor

West Virginia University

Last update posted

Jun 4, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-04. This information was provided to ClinicalTrials.gov by West Virginia University on 2026-06-04.